Creutzfeldt-Jakob disease in a patient treated by etanercept for rheumatoid arthritis (RA): Just a coincidence?

Abstract We describe a patient in whom sporadic Creutzfeldt-Jakob disease (sCJD) occured one year after the onset of etanercept therapy for rheumatoid arthritis (RA). This association could be a chance occurrence. However, TNF-α has been implicated in the pathogenesis of neurodegeneration in sCJD an...

Full description

Saved in:
Bibliographic Details
Published in:Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2010-03, Vol.77 (2), p.174-175
Main Authors: Soubrier, Martin, Haïk, Stéphane, Hauw, Jean-Jacques, Corvol, Jean Christophe, Lyon-Caen, Olivier, Dougados, Maxime
Format: Article
Language:English
Subjects:
Aged
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - immunology
Biologics
Creutzfeldt-Jacob disease
Creutzfeldt-Jakob Syndrome - complications
Creutzfeldt-Jakob Syndrome - immunology
Etanercept
Female
Humans
Immunoglobulin G - therapeutic use
Internal Medicine
Receptors, Tumor Necrosis Factor - therapeutic use
Rheumatoid arthritis
Rheumatology
TNF-blocker
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We describe a patient in whom sporadic Creutzfeldt-Jakob disease (sCJD) occured one year after the onset of etanercept therapy for rheumatoid arthritis (RA). This association could be a chance occurrence. However, TNF-α has been implicated in the pathogenesis of neurodegeneration in sCJD and etanercept might worsen the disease. Such an aggravation has been observed in multiple sclerosis, in which TNF-α is the key mediator of demyelination. It may be of interest studying the impact of treatment with TNF-α antagonists on prevalence and incidence of those neurodegenerative diseases involving TNF-α mediation, such as Alzheimer disease.
ISSN:1297-319X
1778-7254
DOI:10.1016/j.jbspin.2009.05.016